Home > Haematological Malignancies
    • FILTER YOUR SEARCH
    Content Type:

    • Haematological Malignancies

    INTERNATIONAL HAEMATOLOGICAL MALIGNANCIES PARTNER

    US PARTNER

    An Introduction to Haematological Malignancies

    In recent years, advances in our understanding of the pathological mechanisms underlying haematological malignancies have led to improved outcomes. Several novel drug classes are now emerging, including chimeric antigen receptor (CAR) T-cell therapy, molecular targeted therapies, bispecific T-cell engaging antibodies, CD47 blockade therapy and antibody-drug conjugates. Many challenges remain, however, including how best to combine agents and determining where new therapies fit into the treatment paradigm.

    Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.”

    Our supporting partners do not constitute an endorsement of the content on this page.

    Haematological Malignancies Content

    Multiple Myeloma
    Shaji Kumar, ASCO 2021: The EQUATE Trial, a Quadruplet Regimen for Multiple Myeloma

    We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab. The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended […]

    Haematological Malignancies
    Efstathios Kastritis, ASCO 2021: Results from the Phase 3 ANDROMEDA Study

    touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at ASCO 2021 to discuss the updated results from the phase 3 ANDROMEDA study. The abstract ‘Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results […]

    Haematological Malignancies
    touchCONGRESS
    Exploring the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML
    Prof. Uwe Platzbecker, Prof. Valeria Santini, Prof. Andrew Wei Watch Time: 64 mins Available in:

    Watch this two-part activity exploring recent developments around the treatment of higher-risk MDS and newly diagnosed AML. Filmed following the EHA2021 Virtual Congress. Part 1: Watch haematological cancer expert Prof. Uwe Platzbecker review key data from the EHA2021 Virtual Congress Watch Now Part 2: Choose from leading experts who discuss what these data mean for global and regional practice Select An Interview  

    Learning objectives
    Learning Objectives
    • Recall the mechanisms of action and key clinical data for emerging treatments for higher-risk MDS
    • Evaluate current treatments and novel approaches for newly diagnosed AML, including management options when intensive induction therapy is not suitable
    • Discuss the current and future potential of immunotherapy and the use of measurable residual disease (MRD) monitoring in MDS and AML
    Haematological Malignancies, Multiple Myeloma
    Modulation of Apoptosis Pathways in the Biology and Treatment of Multiple Myeloma
    Radhika Bansal, Sagar Rakshit, Weiguo Han

    touchREVIEWS in Oncology & Haematology. 2021;17(1):Online ahead of journal publication

    Multiple myeloma is a plasma cell malignancy that typically develops in individuals in their late 60s with an average survival time of ~8 years.1 Despite recent advances in treatment, multiple myeloma remains largely incurable due to development of drug resistance in tumour cells. Patients often relapse even after autologous stem cell transplant and multiple lines […]

    Multiple Myeloma
    touchCONGRESS
    Advances in the role of BCMA-targeting agents in multiple myeloma: An update from the EHA Congress 2021
    Dr María-Victoria Mateos, Dr Heather Sutherland, Prof. Dr. Niels van de Donk Watch Time: 64 mins Available in:

    Watch this two-part activity exploring recent data for BCMA-targeting agents in multiple myeloma. Filmed following the European Hematology Association 2021 Virtual Congress. Part 1: Watch multiple myeloma expert Dr María-Victoria Mateos review key data from the EHA2021 Virtual Congress Watch Now Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview  

    Learning objectives
    Learning Objectives
    • Recall efficacy data for BCMA-targeting agents in the treatment of multiple myeloma
    • Describe the safety data for BCMA-targeting agents in the treatment of multiple myeloma
    • Discuss how the latest data on BCMA-targeting agents may affect the management of patients with multiple myeloma
    Multiple Myeloma
    touchPANEL DISCUSSION
    Integrating BCMA-targeting agents into the treatment pathway for relapsed/refractory multiple myeloma
    Dr Francesca Gay, Prof. Meletios Dimopoulos, Prof. Dr. Hermann Einsele Watch Time: 29 mins

    Watch a panel of experts discuss the use of BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma.

    Learning objectives
    Learning Objectives
    • Discuss the potential of BCMA-targeting agents to improve outcomes for patients with relapsed/refractory multiple myeloma
    • Identify patients with relapsed/refractory multiple myeloma who may benefit from treatment with a BCMA-targeting agent
    • Use strategies to monitor for and manage the adverse events associated with BCMA-targeting agents
    Leukaemia
    touchROUNDTABLE
    The role of measurable residual disease in acute lymphoblastic leukaemia
    Associate Prof. Aaron Logan, Prof. Joseph Khoury, Dr Nicola Gökbuget Watch Time: 46 mins

    Watch leading experts Aaron Logan, Joseph Khoury and Nicola Gökbuget discuss the importance of measurable residual disease reporting in acute lymphoblastic lymphoma, as well as best practice techniques, potential limitations, and future directions.

    Learning objectives
    Learning Objectives
    • Evaluate the evolving treatment landscape for acute lymphoblastic leukaemia
    • Appraise the benefits and limitations of performing and reporting results for measurable residual disease
    • Summarize how clinicians and pathologists can collaborate to use measurable residual disease testing to guide disease management
    Haematological Malignancies
    New Approaches to Allogeneic Haematopoietic Cell Transplantation
    Cemaleddin Ozturk, Sinem Civriz Bozdag

    touchREVIEWS in Oncology & Haematology. 2021;17(1):Online ahead of journal publication

    Allogeneic haematopoietic cell transplantation (allo-HCT) has a bi-faceted role in the treatment of haematopoietic malignancies. First, allo-HCT gives high-dose chemotherapy a chance to reduce the leukaemic burden; second, it allows graft-originated natural killer and T cells to initiate an adoptive immunotherapy effect against leukaemic cells via tumour-specific antigens, tumour-associated antigens and minor histocompatibility antigens.1–6 Allo-HCT plays […]

    Multiple Myeloma
    touchPANEL DISCUSSION
    Improving outcomes in multiple myeloma with new treatment targets
    CME ACCREDITED Prof. Joseph Mikhael, Dr Cristina Gasparetto, Dr Elena Zamagni Watch Time: 33 mins

    Watch a panel of experts discuss how novel targeted therapies are changing the treatment paradigm for multiple myeloma to achieve the best outcomes for patients.

    Learning objectives
    Learning Objectives
    • Recall the mechanisms of action and data for relapsed/refractory multiple myeloma treatments with novel agents
    • Discuss the adverse event (AE) profiles of treatments with novel targets and how AEs could be managed in clinical practice
    • Describe the possible role of agents with novel targets earlier in the multiple myeloma treatment pathway
    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72